Promise Proteomics
Promise Proteomics specializes in developing and providing advanced mass spectrometry solutions, kits, and standards for bioanalytical scientists. Their mission is to facilitate the quantification and monitoring of therapeutic monoclonal antibodies and other proteins in clinical and research settings, ensuring high accuracy, stability, and reproducibility.
Industries
Nr. of Employees
small (1-50)
Promise Proteomics
Patents
Products
Ready-to-use LC-MS/MS kit for quantifying therapeutic monoclonal antibodies
Standardized kit providing reagents and controls for preparing patient plasma samples for LC-MS/MS quantification of therapeutic monoclonal antibodies to support therapeutic drug monitoring.
Stable-isotope-labelled protein and monoclonal antibody internal standards
High-purity stable-isotope-labelled proteins and monoclonal antibodies produced as internal standards for quantitative LC-MS assays, with high isotopic incorporation and defined stability specifications.
DIGESTIF digestion and LC-MS quality-control reagent
Two-in-one quality-control reagent designed to assess proteolytic digestion efficiency and monitor LC-MS system performance in bottom-up proteomic workflows.
Ready-to-use LC-MS/MS kit for quantifying therapeutic monoclonal antibodies
Standardized kit providing reagents and controls for preparing patient plasma samples for LC-MS/MS quantification of therapeutic monoclonal antibodies to support therapeutic drug monitoring.
Stable-isotope-labelled protein and monoclonal antibody internal standards
High-purity stable-isotope-labelled proteins and monoclonal antibodies produced as internal standards for quantitative LC-MS assays, with high isotopic incorporation and defined stability specifications.
DIGESTIF digestion and LC-MS quality-control reagent
Two-in-one quality-control reagent designed to assess proteolytic digestion efficiency and monitor LC-MS system performance in bottom-up proteomic workflows.
Services
Contract R&D to develop, validate and cross-validate quantitative LC-MS/MS assays for therapeutic proteins, including method comparisons with immunoassays.
Provision of tutorial videos, workshop materials and technical guidance for implementing kit-based LC-MS/MS workflows in clinical laboratories.
Contract R&D to develop, validate and cross-validate quantitative LC-MS/MS assays for therapeutic proteins, including method comparisons with immunoassays.
Provision of tutorial videos, workshop materials and technical guidance for implementing kit-based LC-MS/MS workflows in clinical laboratories.
Expertise Areas
- Therapeutic monoclonal antibody quantification
- Therapeutic drug monitoring (TDM)
- LC-MS/MS and LC-MS/HRMS method development
- Stable-isotope-labelled internal standard production
Key Technologies
- Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
- High-resolution mass spectrometry (LC-MS/HRMS, Orbitrap)
- Stable isotope-labelled (SIL) internal standards
- Bottom-up proteomics (tryptic peptide workflows)
News & Updates
A study on the exposure response relationship of nivolumab and ipilimumab in mRCC patients.
A pharmacokinetic study in patients with colorectal peritoneal metastases.
A study on Atezolizumab exposure in real-world lung cancer patients.
An article discussing toxicities related to Pembrolizumab.
A clinical and pharmacokinetic analysis of hepatotoxicity in NSCLC patients.
A study on quantifying infliximab and adalimumab using LC-MS/MS kits.
A study on the exposure response relationship of nivolumab and ipilimumab in mRCC patients.
A pharmacokinetic study in patients with colorectal peritoneal metastases.
A study on Atezolizumab exposure in real-world lung cancer patients.
An article discussing toxicities related to Pembrolizumab.
A clinical and pharmacokinetic analysis of hepatotoxicity in NSCLC patients.
A study on quantifying infliximab and adalimumab using LC-MS/MS kits.